Topical IL-1-Ra for Treatment of Posterior Blepharitis

NCT00681109 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Posterior Blepharitis

Interventions

DRUG: 2.5% IL-1Ra
DRUG: Placebo
DRUG: 5% IL-1Ra

Sponsor

Reza Dana, MD